Quick Facts: Uses of Mesigyna Instayect

• Main Therapeutic Domain: Contraception
• Primary Function: To assist in the prevention of pregnancy
• Method of Administration: Monthly injectable formulation

---

What Mesigyna Instayect Treats: Main Uses and Benefits

Mesigyna Instayect is a recognized contraceptive method for individuals of reproductive age who seek to prevent pregnancy. As a combined injectable contraceptive, it offers a single-dose monthly formulation to support ongoing fertility management. The formulation works to help reduce the possibility of conception.

Its main purpose is to serve as a reliable means of birth spacing and family planning. The use of this type of hormonal contraception is well-established in many international regions, particularly throughout Latin America, as an option for women seeking a reversible, user-independent regimen. The benefits of using combined hormonal contraceptives, such as preventing unwanted pregnancies, are weighed against the associated risks in clinical use.

Mesigyna Instayect is intended for use by adult female patients of reproductive age who are seeking hormonal contraception. Eligibility is strictly defined by regulatory documents, which establish clear restrictions based on health history, current conditions, and reproductive status.

Populations for Whom Use is Prohibited (Contraindicated)

Classification	Exclusionary Condition
Thrombotic Risk	Presence or history of venous or arterial thrombotic or thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, myocardial infarction), or conditions that precede thrombosis (e.g., transient ischaemic attack).
Malignancy Risk	Known or suspected sex-steroid influenced malignancies (e.g., of the genital organs or the breast).
Hepatic Health	Severe hepatic disease as long as liver function values have not returned to normal, or a presence or history of liver tumours (benign or malignant).
Other Conditions	Diabetes mellitus with vascular involvement; history of migraine with focal neurological symptoms; known or suspected pregnancy; undiagnosed vaginal bleeding.

Age and Physiological Status Rules

• Age: The product is not indicated after menopause, as the contraceptive use is no longer relevant for this group.
• Postpartum: For women who are not breastfeeding, use is not recommended during the period of less than 21 days after delivery due to elevated thromboembolism risk.
• Renal Impairment: Available regulatory data do not suggest a change in treatment for patients with renal impairment.

Regulatory documentation defines who can and cannot use the medicine by prioritizing protection against major health risks, such as cardiovascular complications and hormone-sensitive cancers. These formal contraindications are based on established safety criteria for combined hormonal contraceptives.

Mesigyna Instayect (norethisterone enanthate and estradiol valerate) is a combined hormonal contraceptive whose effectiveness can be significantly reduced by certain other medications. This interaction typically occurs because the other drugs increase the rate at which the body metabolizes or breaks down the contraceptive hormones, leading to lower-than-effective hormone levels in the blood.

It is essential to inform your healthcare provider about all medicines, herbal products, and supplements you are taking. The most notable interactions involve drugs that induce liver enzymes, such as cytochrome P450 enzymes. Reduced contraceptive effectiveness may result in irregular bleeding or unintended pregnancy.

Medications that may reduce contraceptive effectiveness

Category	Examples of Active Ingredients
Anticonvulsants	Phenytoin, Carbamazepine, Phenobarbital, Primidone, Topiramate, Oxcarbazepine
Anti-infectives	Rifampicin (for tuberculosis), some HIV medications (e.g., Ritonavir, Efavirenz)
Herbal Supplements	St. John’s Wort (Hypericum perforatum)

Conversely, some medications may increase the concentration of the contraceptive hormones in your bloodstream, potentially leading to a higher risk of side effects like blood clots. These include certain antifungal agents (e.g., Ketoconazole) or high-dose Vitamin C. Women taking any interacting drug should discuss the need for an alternative contraceptive method or additional non-hormonal barrier methods with a healthcare professional during treatment and for a period after stopping the interacting medication.

The mechanism of action involves the synergistic activity of its two components: norethisterone enanthate (NET-EN) and estradiol valerate (EV). NET-EN, a prodrug, undergoes hydrolysis to yield the active progestin, norethisterone, while EV hydrolyzes to estradiol. Norethisterone acts as an agonist at the intracellular progesterone receptor (PR), and estradiol acts as an agonist at the estrogen receptor (ER), primarily ERalpha and ERbeta.

Targeted tissues include the hypothalamus, anterior pituitary gland, ovaries, cervix, and endometrium. The central action involves a sustained negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis. The progestin component, norethisterone, is critical in suppressing the pulsatile release of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus. This, in turn, reduces the secretion of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) from the anterior pituitary. The resulting reduction in gonadotropin concentrations prevents the midcycle LH surge and inhibits follicular maturation, thereby modulating the ovulatory cascade. Simultaneously, norethisterone acts locally on the cervix, increasing cervical mucus viscosity, and on the endometrium, inducing cellular changes that result in endometrial atrophy.

How to Use Mesigyna Instayect: Administration Guidelines

This section describes the administration guidelines for Mesigyna Instayect, focusing on the dosage, route, and schedule.

---

Administration Protocol

Mesigyna Instayect is provided as a 1 mL oily solution for injection containing a fixed single dose of 5 mg Estradiol valerate and 50 mg Norethisterone enanthate (NET-EN). The medication is intended for use as part of a continuous, long-term cyclic regimen.

Instruction	Detail
Route of Administration	Deep Intramuscular Injection (IM), preferably into the intragluteal region or the upper arm (deltoid muscle).
Injection Technique	The injection must be administered extremely slowly.
Standard Interval	30 days (plus or minus 3 days) (minimum 27 days, maximum 33 days).

---

Timing and Initiation

Administration adheres to a precise monthly schedule, with subsequent injections due regardless of the patient's bleeding pattern. The timing of the first dose defines the regimen:

• Cycle Start: The first dose is typically administered within seven days of the start of menstrual bleeding. No supplementary protection is required if administered during this window.
• Late Start: If the first injection is given more than seven days after the start of bleeding, seven days of supplementary contraceptive protection are required.

Rules for Missed Timing

The established cyclic schedule provides a small tolerance for minor delays. The injection may be administered up to seven days late (33 days from the previous dose) while generally maintaining the contraceptive effect. If the interval is extended beyond this 33-day maximum, the contraceptive efficacy may be compromised.

Population-Specific Constraints

Use is not recommended for women who are breastfeeding less than six months postpartum, or for non-breastfeeding women less than 21 days postpartum. The medication is only indicated for use after menarche.

Research Evidence / Overview of Studies for Mesigyna Instayect

Evidence for Hormonal Prevention of Pregnancy (Contraception)

The primary research for Mesigyna Instayect has largely focused on its main purpose: hormonal prevention of pregnancy. The foundational evidence includes large-scale, international Randomized Controlled Trials (RCTs), some of which were supported and coordinated by the World Health Organization (WHO). These RCTs use rigorous study designs. Researchers monitored hundreds of women to track contraceptive failure rates, which are documented using standardized scientific measures like the Pearl Index. Studies tracked patterns related to contraceptive failure rates, documenting the rates observed in the study populations. Findings describe group patterns, not personal outcomes.

The evidence level for this indication is considered High due to the extensive use of multi-center RCTs and the foundational nature of the regulatory research.

---

Research on Cycle Control and Continuation Patterns

Beyond the primary evaluation, studies explored other outcomes related to daily functioning, examining patterns observed in the menstrual cycle and user continuation with the method. Researchers tracked patient-reported experiences related to bleeding profiles, monitoring the number of days with bleeding or spotting, as well as the incidence of amenorrhea (absence of bleeding). Studies report that a key reason for discontinuation across several trials was dissatisfaction with reported changes in bleeding patterns.

What remains uncertain is the consistency of these patterns across all users globally. Existing data show patterns related to variability in cycle control patterns and continuation rates when comparing findings from studies conducted in different geographic or ethnic groups.

---

Long-Term Study Durations and Follow-up

Clinical trials typically involved follow-up durations ranging from 6 months to 2 years. This intermediate-term data collection provided data used in the original regulatory submission. The research also examined outcomes beyond core evaluation, focusing on changes in specific biological markers. Studies monitored physiological factors by tracking changes in serum lipid profiles, lipoprotein levels, and certain coagulation factors.

While studies extend up to two years, long-term outcomes (beyond three years) are not extensively characterized in the context of the studies' primary endpoints. The majority of recent research is now focused on specific metabolic outcomes in subgroups rather than the long-term continuation of the entire study population.

---

What is Still Uncertain in the Research Landscape

The core endpoints of this monthly injectable were studied, and the data supported regulatory review. However, comparative evidence is lacking that directly places this combination against the newest, low-dose contraceptive technologies now available. Additionally, there is limited information for long-term outcomes extending beyond a few years of continuous use. Research is ongoing, and findings contribute to the broader evidence landscape, but certainty remains low regarding the full range of observed patterns after many years.

Key Studies & References Medical Eligibility Criteria for Contraceptive Use, 5th edition (WHO Guideline)

Common questions about Mesigyna Instayect (FAQ)

Q: Is Mesigyna Instayect the same as other monthly injections?

A: Regulatory documents state that Mesigyna Instayect is a specific type of Combined Injectable Contraceptive (CIC). It contains the hormone combination of estradiol valerate and norethisterone enanthate. This particular formulation and component combination distinguishes it from other monthly injections.

Q: What is the difference between Mesigyna and other birth control methods?

A: Official product information classifies Mesigyna Instayect as a Combined Injectable Contraceptive (CIC). It provides a sustained, once-a-month effect using an intramuscular injection, which is a different method of delivery and schedule compared to daily oral contraceptives or longer-term methods like implants.

Q: Does Mesigyna Instayect cause changes to mood or emotion?

A: According to official regulatory documents, nervousness is listed as one of the common systemic adverse reactions associated with the use of Mesigyna Instayect. Changes to mood or emotion are a recognized potential effect of hormonal medicines, and this specific reaction is noted in the product's safety information.

Q: Can Mesigyna Instayect affect the effectiveness of antibiotic medicine?

A: Regulatory information indicates that certain types of anti-infective medicines, such as the tuberculosis drug Rifampicin, can reduce the effectiveness of the injection. These specific drugs cause the body to break down the contraceptive hormones faster. Regulatory information only explicitly flags the enzyme-inducing anti-infectives as high risk.

Q: Does smoking make using Mesigyna Instayect more risky?

A: Smoking is officially listed as a factor that increases the risk of developing a blood clot (thromboembolism) for all women using combined hormonal contraceptives. This is considered a serious safety concern outlined in the regulatory safety information for this drug class.

Q: Is there a certain time of day the injection is given?

A: The official administration guidelines emphasize adhering to a precise monthly schedule (e.g., 30 pm 3 days between injections). However, the regulatory text does not specify a mandatory time of day for the deep intramuscular injection.

Q: Will Mesigyna Instayect make my menstrual cycle regular?

A: Official product information states that menstrual irregularities are common, especially during the first year of use. This includes spotting, irregular bleeding, and sometimes the complete loss of a period (amenorrhea). These bleeding patterns may stabilize over time, but irregularity is a commonly reported effect.

Q: Does Mesigyna Instayect help with symptoms of Polycystic Ovary Syndrome (PCOS)?

A: The sole approved therapeutic indication for Mesigyna Instayect, according to regulatory documents, is the hormonal prevention of pregnancy. There is no information in the official product label indicating that it is intended or authorized for the treatment of symptoms related to Polycystic Ovary Syndrome (PCOS).

Q: Are there any long-term health risks associated with Mesigyna Instayect?

A: Official safety information highlights that the most serious, though rare, concern for this class of medicine is the risk of Thromboembolic Disorders (blood clots, stroke). While clinical trials provide data for up to two years, official research reports acknowledge that long-term outcomes extending beyond three years of continuous use are not extensively characterized.

Q: Can I use Mesigyna Instayect if I have a history of blood clots in my family?

A: Regulatory guidance identifies a family history of blood clots in a first-degree relative at a young age (e.g., below 50) as a risk factor for venous thromboembolism (VTE). This factor is noted within the official safety constraints for combined hormonal contraceptives.

Q: What is the typical timeframe for side effects to appear after starting Mesigyna Instayect?

A: The timeline for side effects can vary. Regulatory information specifically notes that menstrual irregularities (spotting and irregular bleeding) are common during the first year of use and tend to decrease with subsequent injections.

Q: Has Mesigyna Instayect been studied in teenagers?

A: Regulatory information indicates that this product is only intended for use after menarche (the start of menstruation). The primary body of clinical research supporting the drug’s authorization typically includes adult female patients of reproductive age, often from 18 years onward.

Q: What is the meaning of the hormone names in the product description?

A: The terms 'valerate' and 'enanthate' are chemical designations for the hormone components, estradiol and norethisterone. These components are known as 'esters,' which are essential because they allow the hormones to be dissolved in the oil solution. The oil base ensures the slow, steady release of the hormones from the injection site over the monthly dosing period.

Q: Is Mesigyna Instayect included in national health guidelines or formularies?

A: The World Health Organization (WHO) supports this medication and it is recognized as one of the most widely used combined injectable contraceptives globally. It often features on health guidelines in various countries where it is approved.

Q: Can Mesigyna Instayect be used as emergency contraception?

A: Official regulatory documents state that the sole approved purpose of Mesigyna Instayect is the long-term, cyclic prevention of pregnancy. The injection is not indicated or authorized for use as a form of emergency contraception.

Q: Does Mesigyna Instayect protect against sexually transmitted infections?

A: According to official health guidelines, Mesigyna Instayect, like all hormonal contraceptives, is designed only to prevent pregnancy. It does not provide protection against Human Immunodeficiency Virus (HIV), AIDS, or any other sexually transmitted infections (STIs).

Q: Can taking Mesigyna Instayect affect my skin or acne?

A: Acne and changes to the skin are recognized as potential side effects of hormonal contraceptives in official safety documents. These are generally minor reactions that can vary in frequency among users.

Q: What should I do if I notice an unfamiliar reaction after the injection?

A: Regulatory authorities instruct patients to report any side effects they experience, particularly those not described in the official patient leaflet. This information should be shared with a healthcare provider or submitted directly to the national drug regulatory authority for safety monitoring.

Q: Is Mesigyna Instayect recommended for women over 35?

A: Regulatory safety information notes that increasing age is a factor that raises the risk of a blood clot (thromboembolism) for women using combined hormonal contraceptives. This factor is noted when considering the risk profile outlined in official documents.

Q: Does Mesigyna Instayect affect future fertility?

A: Studies and official information indicate that fertility returns after discontinuing the injection. However, the time taken for ovulation and fertility to return may be slightly delayed compared to non-injectable methods, which is a pattern often seen with injectable hormonal contraceptives containing NET-EN.

Q: Can I stop using Mesigyna Instayect at any time?

A: Stopping the medicine is a personal choice. Official documents state that the contraceptive effect ceases upon discontinuation. If an individual wishes to avoid pregnancy following cessation, it is advised that alternative contraceptive methods be discussed beforehand.

Q: Is loss of bone density a reported concern with Mesigyna Instayect?

A: Loss of bone mineral density is a recognized concern for the general class of injectable hormonal contraceptives, particularly with long-term use. This is a topic of safety review for all such products, though Mesigyna Instayect is a combined injection rather than a progestin-only type.

Q: How does my weight factor into the effectiveness of Mesigyna Instayect?

A: Official safety constraints state that being very overweight (obesity) is listed as a factor that increases the risk of a blood clot (thromboembolism) for women using combined hormonal contraceptives. This is a safety consideration noted in the product's regulatory documentation.

Q: Do other hormonal birth control methods interact with Mesigyna Instayect?

A: Regulatory guidance states that the co-administration of different types of hormonal contraceptives is generally contraindicated. This is to avoid the risk of increased total hormone exposure, especially estrogen, which could lead to a potentially higher risk of serious side effects like thromboembolism.

Q: How does the effectiveness of Mesigyna Instayect compare to oral contraceptives in general?

A: Studies on Mesigyna Instayect report its contraceptive failure rates using measures like the Pearl Index, which is common for all contraceptives. This rate indicates high effectiveness that is comparable to typical effectiveness rates reported for oral contraceptives.

Q: Can users experience nausea after receiving the injection?

A: Nausea (or feeling sick) is a commonly reported side effect associated with the use of hormonal contraceptives in official safety lists. This reaction can vary in frequency among individuals.

How to Store and Dispose of Mesigyna Instayect?

This injection must be stored and handled according to specific regulatory requirements to maintain its stability and effectiveness.

Storage Condition	Requirement
Temperature	Do not store above 30 C (86 F).
Prohibited Environment	Do not refrigerate or freeze the oil-based solution.
Light Protection	Keep the prefilled syringe or ampoule in its original carton to protect the product from light.

---

• Stability and Handling: The contents of the package must be used immediately once the primary packaging is opened; any unused portion must be discarded.
• Child Safety: It is a mandatory requirement to keep this medicine out of the sight and reach of children.
• Disposal Rules: Unused, expired, or leftover product must not be thrown into household trash or wastewater. Disposal must follow local regulations for pharmaceutical waste, often requiring return to a pharmacy or disposal in an approved sharps container.